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Abstract
Background—In the U.S. older adults have low rates of follow-up colonoscopy after a positive
screening FOBT result. The long-term outcomes of these real world practices and their associated
benefits and burdens are unknown.
Methods—Longitudinal cohort study of the 212 patients 70 years or older with a positive
screening FOBT at 4 Veteran Affairs facilities in 2001, followed through 2008. We determined the
frequency of downstream outcomes during the 7 years of follow-up, including procedures,
colonoscopic findings, outcomes of treatment, complications, and mortality based on chart review
and national VA and Medicare data. Net burden or benefit from screening and follow-up was
determined according to each patient’s life expectancy. Life-expectancy was classified into three
categories: best (age 70-79 and Charlson=0), average, and worst (age 70-84 and Charlson ≥ 4 or
age ≥ 85 and Charlson ≥ 1).
Results—56% (118/212) of patients received follow-up colonoscopy, which found 34 significant
adenomas and 6 cancers. 10% (12/118) experienced complications from colonoscopy or cancer
treatment. 46% (43/94) of those without follow-up colonoscopy died of other causes within 5
years of FOBT while 4 died of colorectal cancer. 87% (26/30) of patients with worst life
expectancy experienced net burden from screening, 70% (92/131) with average life expectancy,
and 65% (35/51) with best life expectancy (P for trend = 0.048).
Conclusions—Over a 7-year period, older adults with best life-expectancy are less likely to
experience net burden from current screening and follow-up practices than those with worst life
expectancy. The net burden could be decreased by better targeting FOBT screening and follow-up
to healthy older adults.
INTRODUCTION
In many real world settings, less than 60% of patients receive colonoscopy within 1 year of a
positive FOBT result.1-4 A recent study found many older patients without follow-up are in
poor health or decline follow-up suggesting they should not have been screened in the first
place. 5 In addition, rates of follow-up have shown minimal improvement over the last
decade.3,4,6,7 Despite persistently low rates of follow-up colonoscopy in older adults with
positive screening FOBT results, the long-term outcomes of these real world screening and
follow-up practices have not been described.3,4,8
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The benefit of finding asymptomatic cancer or precancerous polyps that would have caused
symptoms years later must be weighed against immediate burdens of follow-up procedures
and treatments stemming from a positive screening result.9 Randomized trials of FOBT
suggest that a person should have a life expectancy of at least 5 years to derive survival
benefit from screening, otherwise they are only subject to the potential burdens.9,10 We are
not aware of any studies of real world practices that follow older patients for more than 3
years after a positive screening FOBT result to determine whether patients lived long
enough to potentially benefit from detecting large adenomas or early stage colorectal cancer,
or whether they only experienced burdens from follow-up procedures and treatments (e.g.,
false-positive results, repeated testing, complications).3,4 Such information about the
benefits and burdens experienced by older adults with positive FOBT results would help to
guide individualized screening and follow-up decisions in clinical practice.
We describe 7-year outcomes following a positive screening FOBT result in older adults in
real world clinical practice. We took a novel approach of combining VA and Medicare
claims and chart review to follow the downstream outcomes after a positive FOBT result
among patients 70 years or older screened at 4 geographically diverse VA’s. Downstream
outcomes included follow-up testing, polypectomies, cancer diagnoses and treatment,
procedural complications and overall mortality. Net benefit or burden resulting from these
screening and follow-up practices was determined according to each patient’s predicted life-
expectancy.11 The goal is to inform how clinical practice could improve to maximize the net
benefit of FOBT screening and follow-up in older adults.
METHODS
Data Sources and Patients
We conducted a longitudinal cohort study of 212 adults aged ≥ 70 years who had a positive
screening FOBT result during 2001 at 4 VA facilities (Minneapolis, Durham, Portland, and
West Los Angeles) and followed them for 7 years to determine downstream outcomes. We
chose to focus on positive screening FOBT results as FOBT is the most common colorectal
cancer screening test within the VA.12 To identify our cohort, we used outpatient claims
from the VA National Patient Care Database to identify all patients ≥ 70 years who had a
screening FOBT between 1/1/01 and 12/31/01 at the 4 facilities and met our inclusion and
exclusion criteria (n=2410).5 All patients had continuous enrollment in Medicare Parts A
and B and fee-for-service coverage during 1/1/00-12/31/02. Patients were excluded if they
had a history of colorectal cancer or polyps, inflammatory bowel disease, colectomy, or
colostomy, or were not due for screening.5 We used claims from 6 months before their
FOBT and chart review to exclude patients with signs or symptoms that would justify
performance of FOBT for non-screening purposes (e.g., iron-deficiency anemia,
gastrointestinal bleeding, abdominal pain, change in bowel habits, and unexplained weight
loss).5 212/2410 (9%) patients had positive screening FOBT results which were extracted
from the Veterans Health Information Systems and Technology Architecture (VISTA)
laboratory package. If any FOBT cards were positive for occult blood, the FOBT was
considered “positive.”
We used National VA Data Systems as well as inpatient and outpatient Medicare claims
through 12/31/02, to capture follow-up testing within one year of a positive FOBT result
inside and outside the VA system.5 Age was determined on the date of the screening FOBT.
Comorbidity was measured using the Deyo adaptation of the Charlson Comorbidity Index,
derived from administrative data.13,14 Charlson-Deyo scores were calculated from VA and
Medicare inpatient and outpatient claims during the 12 months before the date of the FOBT.
Race and gender were obtained from both VA and Medicare data.
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Next, three investigators (CK, MC, and LW) reviewed VA medical records to determine the
long-term outcomes of screening and follow-up through 12/31/08. The VA computerized
medical records system contains notes from all inpatient and outpatient visits. These notes
contain information about follow-up that occurs outside the VA per patient report to their
VA clinician.15
Outcomes of Screening
First, we categorized patients as having received follow-up colonoscopy related to their
positive FOBT result or not. Patients who did not receive colonoscopy over the 7 years or
had a colonoscopy for GI bleeding or other symptoms unrelated to their positive FOBT
result were categorized as the “no follow-up colonoscopy” group. Patients with follow-up
colonoscopy were categorized according to whether they were diagnosed with cancer,
significant adenoma, or non-significant/normal findings. Significant adenoma was defined
as one or more large adenomas (≥1 cm), 3 or more small adenomas (<1 cm), or any
adenoma with villous pathology based on standard GI guidelines.16 Non-significant or
normal findings included findings of diverticuli, less than 3 small adenomas (<1cm),
angiodysplasia, hyperplastic polyps, and normal mucosa.
Next we determined downstream outcomes over 7 years, in those with and without follow-
up colonoscopy. Outcomes included cancer diagnoses, complications from treatment,
frequency of follow-up testing, and 5-year mortality. Cancer diagnoses included cancer
stage and treatment. Complications included those chart-documented as related to
colonoscopy or cancer treatment (e.g., pain/discomfort, gastrointestinal bleeding, infection,
and death). Frequency of follow-up testing included the number of repeat FOBT tests,
sigmoidoscopies, barium enemas, and/or colonoscopies patients received during the 7 years.
Five-year mortality was determined from the VA Vital Status File. 17
Next 2 authors (CK, LW) reviewed each patient’s outcomes to determine whether they
experienced net benefit or net burden from screening and follow-up. Patients were
considered to have experienced net benefit if they had a significant adenoma/colorectal
cancer on follow-up and lived at least 5 years, even if they had complications or repeat
procedures.18,19 Net benefit or burden was indeterminate for 1) patients with 1-2 small
adenomas who lived at least 5 years because some clinicians believe this group potentially
benefitted from screening20-22 or 2) patients who had a colonoscopy outside of the VA
without an available pathology report and lived at least 5 years. All other patients, including
those with normal findings on follow-up colonoscopy (i,e., false-positive FOBT results),
those without follow-up colonoscopy (i.e., had a positive FOBT result that was not worked-
up), and those who died within 5 years of their FOBT (i.e., subjected to tests for an
asymptomatic disease that would never have affected them), were defined as experiencing
net burden. While net burden may be small in some cases (e.g. those without follow-up who
did not develop cancer), some older adults do experience embarrassment and discomfort
from performing FOBT23,24 and a positive test result may be anxiety-provoking.25
Statistical Analyses
To describe downstream outcomes we observed patients from the date of their positive
FOBT result until death or the end of the study period (12/31/08). To determine the
association between life expectancy and net benefit from screening, we stratified patients
into 3 subgroups a priori: Best Life Expectancy–the youngest and healthiest patients (Age
70-79 and Charlson score = 0) who were expected to live > 10 years; Average Life
Expectancy–the younger patients with increasing comorbidity and the oldest healthiest
patients (age 70-79 and Charlson = 1-3 or age ≥80 and Charlson score = 0) who were
expected to live 5-10 years; and Worst Life Expectancy–the sickest and oldest patients (age
Kistler et al. Page 3













70-84 and Charlson ≥ 4 or age ≥ 85 and Charlson ≥ 1) who were expected to live < 5
years.13 Differences between patients receiving net burden and net benefit were determined
according to worsening life expectancy using the Cochran-Armitage chi-square test for
trend. We used SAS, version 9.1 (SAS Institute, Cary, North Carolina) for all analyses.
The Committee on Human Research at the University of California, San Francisco; the
Committee for Research and Development at the San Francisco VA Medical Center; and the
Institutional Review Board at the Minneapolis VA Medical Center approved the study.
RESULTS
Participant Characteristics
The mean age of the 212 patients was 76.4 years (range 70 to 89 years). Consistent with the
elderly veteran population, 99.5% (211/212) were men and 84.9% (180/212) white (Table
1). 31.1% (66/212) patients died within 5 years of their FOBT result. 5-year mortality was
5.9% (3/51) for patients with best life expectancy, 38.2% (50/131) for patients with average
life expectancy, and 46.7% (14/30) for patients with worst life expectancy which equates to
a life expectancy of 5.4 years.
Outcomes of Screening
Patients with Follow-up Colonoscopy—Among the 118 patients who had follow-up
colonoscopy over the 7 year period, 6(5.1%) patients had cancer, 34 (29%) had significant
adenoma, and 70(59%) had neither cancer nor significant adenoma (Figure 1). One patient
with a normal colonoscopy developed an interval colorectal cancer 5 years later which was
successfully treated but he died a year later of congestive heart failure. Eight patients had
colonoscopies outside the VA without an available pathology report so it is unclear if they
had a significant adenoma or not. No subsequent notes indicated that any of these patients
were ever diagnosed with colorectal cancer. 17% (20/118) of these patients died within 5
years of causes other than colorectal cancer. We also assessed complications of follow-up.
10% (12/118) of patients who underwent colonoscopy or cancer treatment experienced
complications as described in Figure 1. Three of the 6 patients with cancer had
complications from surgical treatment of their cancer (Table 2)–although all eventually
recovered and survived more than 5 years after their positive FOBT. Lastly, 29.4% (10/34)
patients with significant adenomas had three or more follow-up tests over the 7 years,
compared to 20.0% (14/70) of patients with non-significant/normal colonoscopy results.
Patients with No Follow-up Colonoscopy—Among the 44.3% (94/212) who had no
follow-up colonoscopy over the 7-year study period (Figure 1), 6.4% (6/94) were eventually
diagnosed with colorectal cancer, of whom 4 died within a few months of treatment (Table
2). 45.7% (43/94) of patients who did not get a follow-up colonoscopy died within 5 years
of causes other than colorectal cancer. 57.4% (54/94) of patients underwent some form of
follow-up other than colonoscopy, such as repeat FOBT or sigmoidoscopy and 59.3%
(32/54) of those patients had more than one follow-up test over the study period but never a
colonoscopy.
Benefits and Burdens
15.6% (33/212) of patients were diagnosed with cancer or significant adenomas on follow-
up colonoscopy and lived at least 5 years, and were defined as receiving net benefit (see
Table 3). Since it is controversial whether the 22 patients with non-significant adenomas
(<1cm) who lived at least 5 years benefitted from screening we categorized them as
receiving indeterminate benefit as well as the 8 patients for whom we did not have
pathology reports from their colonoscopy. The remaining 149 patients were defined as
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receiving net burden, including: 10 patients who had adenomas removed but died within 5
years; 45 patients with no adenomas of any kind found on colonoscopy (i.e. unequivocal
false positives); and 94 patients who did not have a follow-up colonoscopy. The magnitude
of net burden varied, ranging from false positive results in patients without cancer to cancers
not found because patients declined follow-up (6.4%).
Also, the net burden of these screening and follow-up practices varied across the 3
prognostic groups (Figure 2). 87% of those with worst life expectancy experienced net
burden compared to 70% of those with average life expectancy and 65% of those with best
life expectancy (P for trend =0.048 ). Conversely, 20% (10/51) of patients with best life
expectancy experienced net benefit versus 15.3% (20/131) with average life expectancy and
10.0% (3/30) with worst life expectancy (p for trend=0.25).
DISCUSSION
Even over 7 years after a positive FOBT result, only a little over half of older adults
received follow-up colonoscopy. Among those who received follow-up colonoscopy, more
than a quarter had significant adenomas or cancer detected and treated and lived > 5 years,
potentially benefitting from screening, while approximately 59% (70/118) had no significant
findings on follow-up and 10% experienced complications from colonoscopy or cancer
treatment. Among patients who did not receive follow-up colonoscopy, nearly half died of
other causes within 5 years while 4% ultimately died of colorectal cancer. Patients with
worst life expectancy (life-expectancy of 5.4 years) were more likely to experience net
burden compared to patients with average or best life expectancy. As current guidelines
from the USPSTF and other groups encourage individualized decision-making in patients
over 75,16,26 our study provides data about the consequences following the choice to pursue
or forego follow-up of a positive FOBT result.
The low rate of follow-up colonoscopy found in this study (56%) is similar to that of other
studies in older adults even though the follow-up period in other studies ranged from only a
few months to 3 years whereas we extended the follow-up period to 7 years.1-4,7,8 Patients
may not get follow-up colonoscopy because of the risks of colonoscopy and treatment and
other competing causes of mortality, as perceived either by the physician27 or the patient.5
We found that nearly half of those without follow-up colonoscopy died of causes other than
colorectal cancer within 5 years, suggesting that the decision to forego follow-up
colonoscopy was appropriate for those patients. It also suggests such decisions are occurring
after FOBT results are known rather than following recommendations to avoid screening
FOBT if there is no intention to follow-up a positive result with colonoscopy. As the use of
screening colonoscopy increases, colonoscopy decisions will be made up front and will need
to be better targeted than FOBT or the number of colonoscopies performed in people who
die within 5 years will increase.
Among our patients with follow-up colonoscopy, about a third had colorectal cancer or
significant adenomas, on par with other studies.10,28,29 Strul et al. found the overall
adenoma rate in older adults to be 26%.30 Our study indicates that older patients without
follow-up had a 4% risk of ultimately dying of colorectal cancer in the next 5 years. On the
other hand, undergoing follow-up procedures is not without risk. While prior studies have
suggested minimal complications from colonoscopy in older adults, these studies only
followed patients over a short period.4,31-35 We found complications of follow-up
encompassed more than immediate events. In our cohort, four of the 40 older patients with
cancer or significant adenomas were hospitalized for several weeks as a result of
complications from treatment. In addition, 23% (24/104) of those with follow up
colonoscopy, excluding those with cancer, had 3 or more additional tests over 7 years.
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However, while older adults are often at greatest risk for complications from colonoscopy
and colorectal cancer treatment due to their increasing comorbidity36, they may be most
likely to benefit from screening, especially if they have a substantial life expectancy.
While our study is not a randomized trial, the lengthy follow-up allows us to identify
patients who most likely received net benefit from real world screening and follow-up
practices, i.e., those with significant disease treated as a result of screening and lived more
than 5 years. The choice of a 5 year survival time to achieve benefit is based on the natural
history of polyps18 and randomized trials that shows survival benefit begins around 5 years
after the start of FOBT screening.10 In addition, several of the cancers and adenomas found
in our study were large (>3cm) such that it is reasonable to expect that they would have
caused symptoms within 5 years. As with all screening tests, FOBT does not benefit most
patients because most do not have cancer or significant adenomas. Yet, more than 15.6%
(33/212) of patients aged 70 years and older had colorectal cancer or significant adenomas
successfully treated and lived more than 5 years suggesting that a significant minority
received net benefit from current practices.
It makes intuitive sense that patients with the best life expectancy are more likely to benefit
from screening than those with the worst. This has been shown in cost-effectiveness
analyses,37,38 which are based on numerous methodological assumptions, whereas our study
uses real world data to describe outcomes of screening according to life expectancy. We
found older patients with best predicted life expectancy were less likely to experience net
burden from screening than those with the worst. Our study supports guidelines that
recommend using life expectancy to guide colorectal cancer screening decisions in older
adults and argues against one-size-fits-all interventions that simply aim to increase overall
screening and follow-up rates.16,26 We used the well-validated Charlson-Deyo comorbidity
index because it strongly predicts long-term mortality.14 In our cohort it effectively stratified
patients into groups with widely differing 5-year mortality rates, ranging from 6% for
patients with best life expectancy to 47% for those with worst (life expectancy of 5.4 years)
for whom most would not recommend screening.36 However, more comprehensive
prognostic indices (e.g. incorporating functional status) over more than 5 years are needed to
better guide physicians as they target screening and follow-up to those older adults with
substantial life expectancies.39,40
This study has several limitations. First, our cohort is primarily comprised of men who use
the VA, so the generalizability of our findings to non-white men, women and persons not in
the VA is uncertain. However, the VA is the largest healthcare system in the U.S. so
outcomes of screening and follow-up in this system are likely to have generalizable lessons
for US healthcare. Second, our sample size was small because only 212 (9%) patients had
positive screening FOBT results at the 4 participating facilities in 2001. Third, although we
used Medicare claims data for the first year of follow-up, we relied on chart review for later
outcomes which may miss some complications or testing outside the VA, and we were
unable to find pathology results for 8 patients with a colonoscopy outside the VA, although
all 8 remained alive without colorectal cancer. Fourth, we defined patients as having
benefitted from screening if they had colorectal cancer or significant adenomas detected on
follow-up colonoscopy and treated AND survived more than five years. Others may argue
for a longer or shorter survival length to define benefit in older adults.10,41
In conclusion, systematic reviews of colorectal cancer screening have called for more
studies to assess the net benefit of real world colorectal cancer screening practices to
improve appropriate use and minimize burdens of screening.39 Our study employed a novel
method of following patients with a positive screening FOBT result for 7 years to determine
the net benefit and burden of real world screening and follow-up practices in older adults.
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We demonstrated that older adults with substantial life expectancies are less likely to
experience net burden than those with limited life expectancies. Therefore, through
individualized decision-making the percentage of patients experiencing net burden could be
decreased by better targeting FOBT screening and follow-up to healthy older adults.
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Figure 1. Flowchart of the Long-term Outcomes Following a Positive Screening FOBT Result
(n=212)
* Among the 94 patients who did not have a follow-up colonoscopy related to working-up
their positive FOBT result, 10 patients ultimately underwent colonoscopy to work-up
symptoms that developed over the 7-year period (e.g., hematochezia, unexplained weight
loss, anemia) and 2 patients underwent screening colonoscopy many years later without any
mention of their positive FOBT result from 2001. The 3 patients in the no follow-up
colonoscopy group who died of colorectal cancer all had refused follow-up colonoscopy.5
**8 patients did not have a pathology report available from their colonoscopy performed
outside of VA to determine size or type of polyps detected. Therefore we were unable to
definitively classify them as “significant adenoma” versus “non-significant/normal
findings.” None of these 8 patients have any evidence in their medical records that they ever
were diagnosed with colorectal cancer. Overall, 17% (35/212) patients received follow-up
colonoscopy outside the VA healthcare system.
†Significant adenoma was defined as having an adenoma ≥1 cm, 3 or more adenomas or any
adenoma with villous features.
††One patient was diagnosed with an incidental colorectal cancer and survived more than 5
years.
‡12 patients had complications from colonoscopy: three of the 34 patients with significant
adenomas had notable bleeding following polypectomy–one required hospital admission;
another had a vasovagal episode following epinephrine for bleeding; and one had the
procedure aborted and required a repeat colonoscopy. Two patients had complications from
other testing after their colonoscopy–one had a fall after a barium enema, requiring transfer
to the emergency department but was otherwise unharmed and the other had a
sigmoidectomy to treat a large adenoma complicated by a hypoxic event and a 3-week
hospitalization. Three of the 45 patients with normal colonoscopies had discomfort with the
colonoscopy. Lastly, colonoscopy may have contributed to the death of 1 patient who died
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within 3 days of his colonoscopy although the exact cause of death is unknown per the
medical records. Gray shading indicates patients who potentially benefited from screening.
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Figure 2. Benefits and Burdens of Screening and Follow-up Practices According to Life
Expectancy among 212 Patients Aged 70 Years and Older with a Positive Screening FOBT
Result*
*Net benefit was assigned to those patients diagnosed with a significant adenoma or
colorectal cancer on follow-up colonoscopy who lived at least 5 years after screening, even
if they experienced complications from screening or treatment. Net benefit or burden was
indeterminate if 1) patients had 1-2 small adenomas and lived at least 5 years or 2) patients
had a colonoscopy outside of the VA without an available pathology report and lived at least
5 years . Net burden was assigned to patients who failed to receive colonoscopy after their
positive FOBT result, who had a false-positive FOBT result (i.e.,non-significant findings on
follow-up colonoscopy) , or who had a significant adenoma detected but died within 5
years . Among patients with best life expectancy who experienced net burden the most
common reason was failure to get a follow-up colonoscopy (55%; 18/33) whereas among
patients with average or worst life expectancy the most common reason for net burden was
dying within 5 years of their FOBT (54%;64/118). 5-year mortality was 5.9% (3/51) for
patients with best life expectancy, 38.2% (50/131) for patients with average life expectancy,
and 46.7% (14/30) for patients with worst life expectancy which equates to a life expectancy
of 5.4 years.
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Table 1
Characteristics of Patients Aged 70 years and Older with a Positive FOBT Results (N=212)
Characteristic N (%)
Age, years
 70-74 75 (35.4)
 75-79 93 (43.9)
 ≥ 80 44 (20.8)
Male Gender 211 (99.5)
Race/Ethnicity
 White 180 (84.9)
 Black 30 (14.2)







 A 57 (26.9)
 B 119 (56.1)
 C 21 (9.9)
 D 15 (7.1)
Lived in ZCTA in which ≥ 25% of Adults Had a College Education** 56 (26.4)
Median Income of ZCTA (dollars) 22,378 (9,810-
75,050)
Anti-coagulated with Coumadin 26 (12.3)
History of Prior CRC Screening 117 (55.2%)
Life Expectancy Groups
Best Life-Expectancy (70-79 and Charlson =0) 51 (24.1)
Average Life-Expectancy (70-84 and Charlson=1-3 or ≥85 years and
Charlson=0)
131 (61.8)
Worst Life-Expectancy (70+ and Charlson ≥ 4 or 85+ and Charlson≥1) 30 (14.2)
*
<1% of patients in our cohort had dementia at the time of their screening FOBT test.
**
ZTCA=ZIP Code Tabulation Areas
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Table 2
Outcomes of Patients Diagnosed with Colorectal Cancer According to Whether They Received Follow-up of




Patients who had a follow-up colonoscopy
Best Life
Expectancy
74 year-old active man with no Charlson comorbidities who had a follow-up colonoscopy
which found T2N1M0 colorectal cancer in 2002. He underwent curative hemicolectomy




73 year-old healthy man with no Charlson comorbidities who had a normal follow-up
colonoscopy. In 2006 he suddenly developed hematochezia and colonoscopy found T1N0M0
colorectal cancer for which he underwent curative hemicolectomy. He remained healthy until




Healthy 71 year-old man with no Charlson comorbidities who had a follow-up colonoscopy
which found rectal cancer. He underwent curative right hemicolectomy complicated by
recurrent colostomy leakage. He remained relatively healthy until 2007 when he was




72 year-old man with emphysema who had a follow-up colonoscopy which found T1N0M0
colorectal cancer for which he underwent curative hemicolectomy without complications. He
has had 3 normal follow-up colonoscopies during the study period. He developed renal




81 year-old man with chronic obstructive pulmonary disease who had a follow-up
colonoscopy which found a 3cm colorectal cancer without metastases. He underwent
curative hemicolectomy, developed delirium requiring prolonged hospitalization, but




81 year-old with diabetes and mild heart failure who had a follow-up colonoscopy which
found near obstructing colorectal cancer. He was referred for surgery but became
unresponsive and required emergent colectomy. He recovered from surgery but developed
progressive renal failure and remains alive in a nursing home.
Worst Life
Expectancy
74 year-old man with severe rheumatoid arthritis on chronic steroids, emphysema, and
prostate cancer who had a follow-up colonoscopy which found a T1N0M0 colorectal
cancerous polyp which was removed. Given a possibly inadequate resection, he had a sub-
total colectomy complicated by repeat hospitalizations for recurrent wound infections and
bowel obstruction. His chronic obstructive pulmonary disease worsened but he remains alive.
Patients who did not have a follow-up colonoscopy
Best Life
Expectancy
77 year-old active man with prostate cancer on androgen deprivation therapy (this
comorbidity was missed by claims data) who had a positive FOBT 2001. He was sent to GI
clinic but adamantly refused colonoscopy since “he has prostate cancer, he doesn’t want to
know if he has colon cancer.” He agreed to repeat FOBT 4 years later which was positive and
at that time was persuaded to have a colonoscopy which found T3N0M0 colon cancer. He
underwent curative hemicolectomy 2006 and remains alive.
Best Life
Expectancy
79 year-old healthy man with no Charlson comorbidities who had a positive FOBT 2001 but
repeatedly declined colonoscopy over the next 6 years as his hematocrit slowly fell. In 2007
he developed hematochezia and colonoscopy found two obstructing colorectal cancers.
Colonoscopy was complicated by aspiration requiring intubation delaying surgery for several
weeks. He underwent a hemicolectomy in 2007 which was complicated by renal failure and




75 year-old active man with diabetes who had a positive FOBT 2001 and his VA physician
recommended colonoscopy. Instead he had a sigmoidoscopy in 2001 which as done privately
and was normal per patient report. He felt well until he developed hematochezia in 2006 and
colonoscopy found Stage 3 colorectal cancer treated with resection, chemotherapy, and




76 year-old man with a history of a myocardial infarction and coronary stents who had a
positive FOBT 2001 and was referred for colonoscopy. Instead he had a barium enema and
sigmoidoscopy due to his heart disease, which both found an obstructing colorectal cancer.
Further work-up found widely metastatic disease. He underwent palliative hemicolectomy
2001 complicated by a myocardial infarction, abdominal abscesses, and delirium requiring
prolonged hospitalization. He enrolled in hospice 2002 and died shortly afterwards of





















79 year-old obese man with diabetes on coumadin for atrial fibrillation who had a positive
FOBT 2001 and scheduled for colonoscopy but he suddenly developed abdominal pain and
narrow caliber stools so had a barium enema 2001 which found T3N1M0 colorectal cancer.
He was treated with hemicolectomy and declined adjuvant therapy. He was diagnosed with
metastatic disease 2001 and died shortly afterwards of metastatic colorectal cancer.
Worst Life
Expectancy
81 year-old man with stage III congestive heart failure, emphysema, diabetes with end-organ
damage who had a positive FOBT 2001 but refused colonoscopy since he had one in 1987 and
never wanted another. He developed progressive anemia and had a colonoscopy 2002 which
found Stage 2 colorectal cancer. He underwent hemicolectomy which was complicated by
pneumonia and he died shortly afterwards in the hospital.
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Table 3
Downstream Outcomes Classified According to Benefits and Burdens from Screening and Follow-up
Practices for Patients Aged 70 years and Older with a Positive FOBT Result (N=212)
Downstream Outcomes (N) Examples Net Benefit or
Net Burden
Follow-up Colonoscopy (N=118)
   Cancer (N=6)
FOBT led to diagnosis of CRC
and patient lived ≥5 yrs (N=6)
74 year-old man, status post coronary artery bypass
graft, otherwise healthy, with a curative resection for
rectal cancer. Two repeat colonoscopies were negative
for recurrence. He remains healthy
Net Benefit
Significant Adenoma (N=34)
1) FOBT led to diagnosis of a
 significant adenoma and
 patient lived ≥5 years
 (N=27)
79 year-old man who was relatively healthy with a large
adenoma (1.5 cm) on colonoscopy. He had 4 repeat
colonoscopies over 7 years which found adenomas. He
remains healthy.
Net Benefit
2) FOBT led to diagnosis of a
 significant adenoma but
 patient died within 5 years
 (n=7)
74 year-old man with severe heart disease with an
implanted cardiac defibrillator, dependent in several
instrumental activities of daily living and a history of
multiple falls who had 2 adenomas, one large (2 cm),
found on colonoscopy. He suffered a broken hip in 2003




1) FOBT found 1-2 small
 non-villous adenomas or
 indeterminate pathology
 and person lived ≥5 years
 (n=30)
76 year-old man who was independent in instrumental
activities of daily livings with 2 small adenomas (3mm,
8mm) found on colonoscopy. He had several additional
procedures: Repeat FOBTs in 2002 and 2004 and repeat
colonoscopy in 2005- all negative. He remains healthy.
Indeterminate
2) FOBT found no adenoma
 and person lived ≥5 years
 (N=35)
76 year-old man who had peripheral neuropathy with 2
hyperplastic polyps found on colonoscopy. He had
repeat testing with a normal colonoscopy in 2006 and no
further screening was recommended. He remains alive
but quite ill.
Net Burden
3) FOBT found no significant
 adenomas and person died
 within 5 years (N=13)
75 year-old man with end-stage chronic obstructive
pulmonary disease on home oxygen with multiple ER
visits for dyspnea with 1 hyperplastic polyp found on
colonoscopy. He was diagnosed with inoperable3-vessel
coronary disease and severe aortic stenosis in 2004 but
had a repeat colonoscopy which was negative. His
angina worsened and he died in 2005.
Net Burden
No Follow-up Colonoscopy (N=94)
1) Had No Other Work-Up
after +FOBT (N= 40)
73 year-old man status post stroke with aphasia and left
hemiparesis, coronary disease status post coronary
artery bypass graft, and chronic obstructive pulmonary
disease, who had screening at a preventive visit despite
physician note indicating patient had < 5 year life
expectancy and did not recommend screening. His
physician recommended against further work-up and he
progressively declined and died in 2002 in hospice.
Net Burden
2) Had other work-up after
+FOBT (N=54)
80 year-old man with gout and arthritis who had a
positive FOBT in 2001, followed by repeat negative FOBT
in 2004. He never had follow-up colonoscopy. He
moved to a VA nursing home in 2007 and remains alive.
Net Burden
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